[Pisd]

I think compliance letter spiked it..buying back lower.. OKYO$...

[Sirpeter]

Nothing wrong w/ taking profits but I'll wait

[Pisd]

Took half back $2.45.. OKYO$...

[Pisd]

https://ih.advfn.com/stock-market/NASDAQ/okyo-pharma-OKYO/stock-news/91915460/form-6-k-report-of-foreign-issuer-rules-13a-16

[Sirpeter]

I was going to take profits but the chart says no until over $5

[Pisd]

..took the awesome profit w/no news.. keeps climbing...

[glenn1919]

OKYO........................................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

[Sirpeter]

Look'n great

[glenn1919]

OKYO...............................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

[StocksNcash]

Ok Boris and good luck👍

[Boris the Spider]

Not a pump n dump. A handful of shares were sold AH to make it look like that because someone is hoping to buy cheap positions at the open Monday.
I believe the early dry eye results in clinic look promising and that is leaking out. The retinal pain indication is a new market for the eyedrop.
I truly believe OKYO will take off big this year. Of course there will be ups and downs. Trees dont grow to the sky...

[glenn1919]

OKYO...........................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

[StocksNcash]

Hey Boris, sorry didn’t want to get anyone upset here but if you don’t know what a pump N dump looks like then your in the wrong game. But good luck to you

[Boris the Spider]

Pump and dump on a handful of after hours shares. LOL

And you idiots think this is some big dump. LOL

Talk to me in a couple weeks when it is a double or triple.

[StocksNcash]

VANCOUVER, BC, July 26, 2023 (GLOBE NEWSWIRE) -- Nextgen Food Robotics Corp. (the "Company" or "NextGen") (NEO:NGRB) (OTC PINK:NGRBF) (Frankfurt:O83), a leading innovator in food technology, is excited to announce its plans to launch the beta, version 1.0, of its Lily app (“Lily” or “Lily App”), for release with a select beta testing group. The rollout of the Lily beta program and the initial build of the Lily app, represents a significant milestone in Nextgen’s ongoing commitment to the way we experience and interact with food, leveraging the latest in AI technology and large language models (“LLMs”).

The Lily App strives to transform the food industry by providing users with personalized food recommendations, automated meal-planning, and seamless native restaurant and grocery ordering functionality. By leveraging the cutting-edge GPT-4, the latest version of OpenAI's powerful large language model, NextGen aims to offer an unparalleled user experience that caters to individual tastes and preferences.

The beta launch of Lily represents a pivotal step in NextGen's mission to enhance customer convenience and satisfaction in the food sector. Users will be able to access a wide range of features, including:

[StocksNcash]

NGRBF keep and eye out! $$$$$$

[StocksNcash]

Pump and dump just what I thought sorry guys

[Boris the Spider]

Phase 2 trial for corneal pain. Another market.
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

[Boris the Spider]

OKYO heading back to $7. Huge upside potential. Unmet need for dry eye. Lipid drop was a brilliant move. Makes sense. Results of clinic trickling in must be promising.

[StocksNcash]

Could see a sell of later today like I said in my last post it’s being pumped for this morning Got to watch this one good luck

[AJ Freely]

$OKYO - Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain Following Announcement of Clinical Trial Agreement with Tufts Medical Center
👆Up 6.3% Pre-Market/ Current Price $2.05

[ErnieBilco]

You can see the frontloading yesterday on the chart. I'm not in but will watch to see how it finishes the day.
It is overbought for sure.

[Boris the Spider]

Looks like its doing well in clinic. Good news from patients leaking out.
Lets hope it continues.
Was 7 bucks for a reason. It will get back there soon at this rate.
$5B market for dry eye.

[StocksNcash]

This is being pumped for tomorrow morning

[oldstocks]

OKYO SHORT Coverings.
6/30/2023 46,700 shares $53,238.00 -30.0% 0.2% 0.5 $1.14
6/15/2023 66,700 shares $86,376.50 +1.2% 0.3% 0.7 $1.30
5/31/2023 65,900 shares $102,804.00 -22.8% 0.3% 0.3 $1.56
5/15/2023 85,400 shares

Each report shows OKYO shorts have covered.
OKYO hit $1.34 today.
The last 10 days the stock has been trending up.
Lets hope the shorts cover before they cause another 52 week high of $7.00

[oldstocks]

Where did all the OKYO fans go? OKYO has a history of spikes, the last one went to $1.80 and before that it went to $3.20 and one went to $7 which was the 52 week high.
Good time to be in while others are sleeping on the idea of OKYO
Buy low and hope to catch one of the bigger spikes.

[oldstocks]

OK YO let it rip i got filled 1 share yesterday.
Friday I got filled 100 shares.
Seems hard to get bargain prices on this stock.
Wait until people can use this product to clear their eyes and see the value of this stock.
All jokes to the side this stock has a history of dips and rips. So lets see a dip so my buy order can fill completely.

[Triple nickle]

Being pumped this morning

[glenn1919]

OKYO..................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

[oldstocks]

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease. First patient first visit is presently expected to occur within the next two weeks.
“Our primary focus continues to be on advancing the clinical development of OK-101 as a potential treatment option for dry eye disease, a chronic ocular condition that affects roughly 700 million people worldwide,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma. “With the activation of our first clinical site we are now very close to the opening of the OK-101 phase 2 trial and are looking forward to initiating enrollment and completing the trial before the end of the year."

About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further information, please visit the Company's website at www.okyopharma.com

The person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.

Enquiries:

OKYO Pharma Limited Gary S. Jacob, Ph.D., Chief Executive Officer [phone]
Investor Relations Paul Spencer [phone]
Optiva Securities Limited
(Broker) Robert Emmet [phone]

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

[glenn1919]

OKYO..........................................https://stockcharts.com/h-sc/ui?s=OKYO&p=W&b=5&g=0&id=p86431144783

[oldstocks]

OKYO Pharma Announces Director Acquires Shares, Stock up 10%

[subslover]

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
March 16 2023 - 03:01AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208). ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.
OKYO is presently in the process of activating those clinical sites planned for the trial, and preparing the clinical trial drug product OK-101 for shipment to those sites involved in the double-blind, placebo-controlled trial, along with other activities needed for initiating the trial. OKYO is now anticipating the first-patient first-visit initiation of the trial in early Q2 2023 and still looking to release top-line data from this trial in Q4 2023.

“We are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd.

About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.

About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further information, please visit the Company's website at www.okyopharma.com

The person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.

Enquiries:

OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer [phone]

Investor Relations Paul Spencer [phone]

Optiva Securities Limited
(Broker) Robert Emmet [phone]




Primary Logo

OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more OKYO Pharma Charts. OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more OKYO Pharma Charts.
Latest OKYO Messages
Count Crypto Wed Mar 1, 2023 7:44 PM (14 days ago)
Seems too quiet for the potential. Need to

oldstocks Tue Feb 28, 2023 6:56 AM (16 days ago)
OKYO Pharma Announces Custom Clearance of GMP Packaged

oldstocks Tue Feb 28, 2023 12:42 AM (16 days ago)
Interesting afterhours trading. I bet OKYO will fluctuate.

PStockPickz Mon Feb 27, 2023 2:52 PM (16 days ago)
Interesting

PennystockID2017 Thu Feb 23, 2023 1:01 PM (20 days ago)
who selling OKYO? This should see a short

PennystockID2017 Thu Feb 23, 2023 5:49 AM (21 days ago)
Today's news is very big should see $3.50

LuckyLovie Sun Feb 19, 2023 1:06 AM (25 days ago)
By the looks of the trading chart hit

Boris the Spider Sun Feb 19, 2023 12:21 AM (25 days ago)
$5B dry eye market. OKYO well positioned now.

Spicknspan Sat Feb 18, 2023 4:08 PM (25 days ago)
DAMN!

behzadzorro Fri Feb 17, 2023 3:03 PM (26 days ago)
Is it real?!

See More Posts on OKYO Message Board
News
Press Releases
All News
FEATURED New Break Increases Land Position at its Moray Project
Wed Mar 15, 2023 1:34 PM (18 hours ago)
FEATURED Predictmedix Announces Production of AI-Powered Mobile Application to Detect Impairment from Alcohol and Cannabis
Wed Mar 15, 2023 12:01 PM (19 hours ago)
FEATURED Dinewise Signs Multi-Year Service Contract with Leading Data Engineering Company.
Wed Mar 15, 2023 12:00 PM (19 hours ago)
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
Edgar (US Regulatory) • Thu Mar 16, 2023 7:00 AM (11 minutes ago)
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
GlobeNewswire Inc. • Thu Mar 16, 2023 3:01 AM (4 hours ago)
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
Edgar (US Regulatory) • Wed Mar 15, 2023 4:16 PM (15 hours ago)
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
Edgar (US Regulatory) • Wed Mar 15, 2023 7:01 AM (1 day ago)
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)
Edgar (US Regulatory) • Tue Mar 14, 2023 4:06 PM (2 days ago)
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
GlobeNewswire Inc. • Tue Mar 14, 2023 3:00 AM (2 days ago)
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
Edgar (US Regulatory) • Mon Mar 13, 2023 4:16 PM (3 days ago)
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
GlobeNewswire Inc. • Mon Mar 13, 2023 4:15 PM (3 days ago)
Notice of Effectiveness (effect)
Edgar (US Regulatory) • Thu Mar 09, 2023 6:07 AM (1 week ago)
More News Articles

OKYO Pharma (NASDAQ:OKYO)
Intraday Stock Chart
Thursday 16 March 2023 Click Here for more OKYO Pharma Charts.

[Count Crypto]

Seems too quiet for the potential. Need to market better imo

[oldstocks]

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was recently shipped from Europe, has cleared customs in the United States.??
OKYO is now in the process of having randomization codes generated for its double blinded placebo-controlled trial, along with other activities needed for initiating the trial, including authorization of those clinical sites planned for the Phase 2 clinical trial. Once these activities are completed, the drug for the study is planned to be shipped to those sites involved in the trial. OKYO is anticipating the first-patient-first visit in Q1 2023 and looking to release top-line data from this trial in Q4 2023.
“Initiation of the first-in-human Phase 2 trial for OK-101 to treat DED has been a central and critical goal for the company for the past 18 months,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd. “We are excited to be very close now to moving this drug into clinical trials and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs.”
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 has been shown to produce anti-inflammatory and neuropathic pain-reducing activities in mouse models of DED and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further information, please visit the Company's website at www.okyopharma.com
The person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.
Enquiries:
Continue reading on GlobeNewswire

[oldstocks]

Interesting afterhours trading. I bet OKYO will fluctuate.

[PStockPickz]

Interesting

[PennystockID2017]

who selling OKYO? This should see a short squeeze soon

[PennystockID2017]

Today's news is very big should see $3.50 today. OKYO is up 11% in london trading

[LuckyLovie]

By the looks of the trading chart hit high of 6+...I betcha there are no shortages of dry eyes anywhere...allot are wet crying eyes,honey I bought at the high again,YUP maybe next yr will break even...typical buy on the rumor, sell the news...lol

[Boris the Spider]

$5B dry eye market. OKYO well positioned now.

This will be a $10 stock near term. Once approved, blue sky territory because it is a lipid vehicle for dry eye plus antiinflammatory for irritation and pain relief. I love this stock.

[Spicknspan]

DAMN!

[behzadzorro]

Is it real?!

[INFINITI]

Bam

[INFINITI]

Let’s gooo

[makinezmoney]

$OKYO: BOOoommmmmmmmmmmmmmmm...............just hit 6.50


Finally got Discovered ??


Looks like it


GOOOOOOOOOOOOO $OKYO

[makinezmoney]

$OKYO: Got the FDA IND Clearance for Dry-EYE-Disease


Just 2 weeks ago.

This bad boy has alotta upside .......... remember $KALA ???


Now at $1.99

https://twitter.com/okyopharma









GO $OKYO

[crudeoil24]

OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The GPCRs is the family of membrane proteins involved in many biological processes. GPCRs is used for the treatment of various conditions, including cardiovascular disease, cancer, and diabetes. Its product pipeline includes OK-101 for Dry Eye Disease (DED), OK-101 for Non-ophthalmic Indications, and OK-201 to treat corneal neuropathic pain. The OK-101 is its lead preclinical product candidate, which is focused on keratoconjunctivitis sicca commonly known as DED which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The OK-201 is a non-opioid analgesic for ocular pain management without side effects and the potential abuse associated with opioid medications.